Fundraising may be selective, but it is still open for managers that can clearly differentiate themselves.
That was the message from two new closes this week. Align Capital Partners said it hit hard cap on two funds at the same time, raising more than $1.1 billion across ACP IV and Collaborate II, while Kos Biotechnology Partners announced a third close for its global life sciences fund at $123 million (€106 million).
For Align, the raise is the sharper signal. The lower-middle-market private equity firm said ACP IV closed at $770 million and Collaborate II at $375 million, with both funds reaching their respective hard caps, according to the firm and Business Wire. Align began fundraising in April and completed the process on June 15, making for a relatively quick close in a market where managers are often spending longer on the road.
The two-fund result also underscores the appeal of a platform that can offer more than one product to LPs. Alongside its core buyout vehicle, Align has an independent sponsor-focused strategy, giving investors exposure to a familiar lower-middle-market theme in different formats, the firm said.
Kos Biotechnology’s third close points to a similar dynamic, albeit in a more specialized corner of the market. The firm said it raised $123 million for its inaugural global life sciences fund, with support from institutional investors and family offices and Hellenic Development Bank of Investments as lead investor, according to PR Newswire and related coverage. The fund launched in December 2025.
Taken together, the two raises fit a broader pattern in private equity fundraising: the market has narrowed, but it has not closed. Capital is increasingly concentrating around managers with a clear niche, strong positioning and a credible LP base.
That theme is consistent with the latest market commentary. PitchBook’s 2026 outlook says specialist managers accounted for 73.9% of all capital raised in 2025, while its US fundraising note says the top 10 funds could capture more than 40% of fundraising capital this year. Norton Rose Fulbright has likewise described a market in which capital is concentrating around a smaller share of funds, with only about 25% to 30% of 2025 private equity fundraising going to broad, multi-sector buyout funds.
With Intelligence has also pointed to a lower close rate for marketed deals in the second half of 2024, while Financial Times and Pensions & Investments have highlighted slower exits and growing LP scrutiny over how quickly managers can return capital. That backdrop helps explain why successful closes like Align’s and Kos’s are newsworthy: they show that the fundraising channel remains open, but largely for managers that can articulate a differentiated strategy.
Align is a good example of that dynamic in the lower middle market, where investors can underwrite a repeatable playbook and a familiar strategy set. Kos, meanwhile, shows that a sector-specialist platform can still pull in meaningful capital even without broad market momentum, so long as it can present a focused thesis and a concentrated investor base.
The message for the market is not that fundraising has become easy. It has not. But these latest closes suggest that capital remains available for managers that can offer LPs something specific to believe in.
